Short Script: Why MOTS-C Works for Some People and Not Others

Your cells received the signal. They just couldn't act on it.

That's the most common reason MOTS-C doesn't work, and understanding why requires understanding what MOTS-C actually is and where it sits in a much larger chain.

MOTS-C is a peptide encoded not in your nuclear DNA but in your mitochondrial DNA, which makes it unusual because almost nothing useful is encoded there. It gets released from the mitochondria into the cell, then into circulation, and it functions as a messenger, something closer to a signal flare than a drug. It tells the rest of the body that energy systems need to shift. The way it does that is by activating something called AMPK, which stands for AMP-activated protein kinase and is essentially the cell's low-fuel sensor. When energy goes low, AMPK flips on and tells the cell to burn fat, build new mitochondria, and become more sensitive to insulin. MOTS-C is one of the things that pulls that trigger.

That's the whole chain: mitochondria produce MOTS-C, MOTS-C activates AMPK, AMPK drives the metabolic adaptations you're after.

The problem is that MOTS-C is only step one. If the rest of the chain is broken, the signal goes nowhere.

The first place the chain can break is at the mitochondria themselves. A 2020 study looked at what happens when you add MOTS-C directly to cells carrying a specific mitochondrial DNA mutation, the 3243 A to G mutation, which causes severe mitochondrial dysfunction. Neither exogenous MOTS-C added from outside the cell nor endogenous MOTS-C produced inside it improved mitochondrial function in those cells at all. The damage was too deep. The machinery that was supposed to respond to the signal simply could not respond.

That study used cells with a genetic mutation, which is different from the accumulated mitochondrial damage most people carry, but the principle transfers. Mitochondria take damage over time from oxidative stress, poor sleep, excess calories, and sedentary living, and damaged mitochondria are less capable of running the downstream processes that AMPK is supposed to kick off. You can flood the system with signal and get very little back if the equipment receiving that signal is compromised.

This is why the sequencing matters. SS-31 is a peptide that targets the inner mitochondrial membrane and reduces what's called cardiolipin oxidation, which is a specific type of structural damage that impairs how efficiently mitochondria produce energy. Spending four to eight weeks repairing that damage before introducing MOTS-C gives the system something functional to work with. The signal lands and the machinery can actually run.

The second place the chain can break is at AMPK itself, and this one is tied directly to exercise and body composition.

Here's something worth understanding: MOTS-C is not primarily a pharmaceutical compound. It's a hormone your body already makes. A 2021 study in Nature Communications measured MOTS-C levels in skeletal muscle before and after exercise and found that muscle MOTS-C increased 11.9-fold during exercise. Circulating levels returned to baseline within four hours of finishing. What that tells you is that in an active person, this pathway is already being triggered regularly, multiple times a week, and the cells that respond to MOTS-C are already adapted to hearing that signal and acting on it.

In a sedentary person, two things have happened. The AMPK pathway has been chronically underused, so the cellular machinery is less primed to respond. And if that person is also carrying significant excess body fat, the problem compounds because AMPK activity is measurably suppressed in insulin resistant states. The 2013 paper in the Journal of Clinical Investigation showed that AMPK inhibition is an early event in the development of insulin resistance, and that exercise-induced AMPK activation is specifically attenuated in people with obesity. The signal is already fighting through more resistance before the peptide even enters the picture.

The obese mouse data from the foundational 2015 Cell Metabolism study showed that MOTS-C prevented diet-induced obesity and improved insulin sensitivity through AMPK activation via the folate cycle. Those results were real. But those mice were in a controlled setting, not dealing with years of accumulated mitochondrial dysfunction and chronically suppressed AMPK the way a sedentary person in their mid-forties is. The baseline is different.

Exercise is not optional context here. It is part of the mechanism. Without it, you are asking exogenous MOTS-C to do work that your own 11.9-fold endogenous release would be doing if the system were active.

The third place the chain can break is timing and frequency. Because circulating MOTS-C returns to baseline within four hours, a single weekly injection means the signal is active for roughly four hours out of every 168. The 2021 study that showed meaningful improvements in grip strength, stride length, and walking capacity in aging mice used a three-times-per-week protocol. That frequency better mirrors what an exercising system would be experiencing naturally.

Timing matters too for the same reason. If the peptide's window overlaps with your highest energy demand, whether that's a workout or a physically demanding part of your day, the AMPK activation lands when the downstream machinery is most primed to use it.

None of this means MOTS-C doesn't work. It means MOTS-C works the way a hormone works, which is by sending a signal into a biological system, and the response you get is proportional to how well that system is functioning.

The peptide was never doing the work. It was always asking your cells to do it. Whether they can depends entirely on what you've built for them to work with.

---

References

1. Ahn CH, Choi EH, Kong BS, Cho YM. "Effects of MOTS-c on the mitochondrial function of cells harboring 3243 A to G mutant mitochondrial DNA." Molecular Biology Reports. 2020;475:4093-4098. Finding: Neither exogenous nor endogenous MOTS-C improved mitochondrial function in cells with severe genetic mitochondrial DNA damage 3243 A>G mutation. Source
2. Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. 2021;121:470. Finding: Skeletal muscle MOTS-C increased 11.9-fold after exercise; circulating levels returned to baseline within 4 hours. Late-life treatment 3x/week improved grip strength, stride length, and walking capacity. Source
3. Lee C, Zeng J, Drew BG, et al. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism. 2015;213:443-454. Finding: MOTS-C prevented diet-induced obesity and improved insulin sensitivity in mice via AMPK activation through folate cycle inhibition. 00061-3/fulltext Source
4. Ruderman NB, Carling D, Cline GW, et al. "AMPK, insulin resistance, and the metabolic syndrome." Journal of Clinical Investigation. 2013;1237:2764-2772. Finding: AMPK inhibition is an early event in insulin resistance development; exercise-induced AMPK activation is attenuated in patients with obesity. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness